Advisors Asset Management Inc. Sells 4,370 Shares of DaVita Inc. $DVA

Advisors Asset Management Inc. cut its holdings in DaVita Inc. (NYSE:DVA) by 19.4% during the 2nd quarter, Holdings Channel reports. The firm owned 18,186 shares of the company’s stock after selling 4,370 shares during the period. Advisors Asset Management Inc.’s holdings in DaVita were worth $2,591,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. National Pension Service grew its position in shares of DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after buying an additional 84 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Y.D. More Investments Ltd purchased a new stake in DaVita in the first quarter worth $35,000. Mid American Wealth Advisory Group Inc. purchased a new position in DaVita during the 2nd quarter valued at $36,000. Finally, Ameritas Advisory Services LLC purchased a new position in DaVita during the 2nd quarter valued at $47,000. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of several research analyst reports. Barclays dropped their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. TD Cowen cut their price objective on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Bank of America decreased their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Finally, Zacks Research cut DaVita from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 30th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $148.00.

DaVita Stock Performance

Shares of NYSE DVA opened at $119.68 on Friday. The company has a 50 day simple moving average of $125.02 and a two-hundred day simple moving average of $133.76. DaVita Inc. has a fifty-two week low of $113.97 and a fifty-two week high of $179.60. The company has a market capitalization of $8.45 billion, a price-to-earnings ratio of 12.33, a P/E/G ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the previous year, the company earned $2.59 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.